Abstract
It is well known that type-2 diabetes mellitus (T2D) is increasing worldwide, but also the autoimmune form, type-1 diabetes (T1D), is affecting more people. The latest estimation from the International Diabetes Federation (IDF) is that 1.1 million children and adolescents below 20 years of age have T1D. At present, we have no primary, secondary or tertiary prevention or treatment available, although many efforts testing different strategies have been made. This review is based on the findings that apolipoprotein CIII (apoCIII) is increased in T1D and that in vitro studies revealed that healthy β-cells exposed to apoCIII became apoptotic, together with the observation that humans with higher levels of the apolipoprotein, due to mutations in the gene, are more susceptible to developing T1D. We have summarized what is known about apoCIII in relation to inflammation and autoimmunity in in vitro and in vivo studies of T1D. The aim is to highlight the need for exploring this field as we still are only seeing the top of the iceberg.
| Original language | English |
|---|---|
| Article number | 932 |
| Pages (from-to) | 1-13 |
| Number of pages | 13 |
| Journal | International Journal of Molecular Sciences |
| Volume | 22 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published (in print/issue) - 19 Jan 2021 |
Bibliographical note
Funding Information:This work was supported by Odd Fellows Grand Lodge, Sweden, the Swedish Diabetes Association, Funds of Karolinska Institutet, the Swedish Research Council, Novo Nordisk Founda-tion, the Family Erling-Persson Foundation, Strategic Research Program in Diabetes at Karolinska Institutet, the Stichting af Jochnick Foundation, and the ERC-EYLETS 834860.
Funding Information:
Funding: This work was supported by Odd Fellows Grand Lodge, Sweden, the Swedish Diabetes Association, Funds of Karolinska Institutet, the Swedish Research Council, Novo Nordisk Foundation, the Family Erling-Persson Foundation, Strategic Research Program in Diabetes at Karolinska Institutet, the Stichting af Jochnick Foundation, and the ERC-EYLETS 834860.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Funding
This work was supported by Odd Fellows Grand Lodge, Sweden, the Swedish Diabetes Association, Funds of Karolinska Institutet, the Swedish Research Council, Novo Nordisk Founda-tion, the Family Erling-Persson Foundation, Strategic Research Program in Diabetes at Karolinska Institutet, the Stichting af Jochnick Foundation, and the ERC-EYLETS 834860. Funding: This work was supported by Odd Fellows Grand Lodge, Sweden, the Swedish Diabetes Association, Funds of Karolinska Institutet, the Swedish Research Council, Novo Nordisk Foundation, the Family Erling-Persson Foundation, Strategic Research Program in Diabetes at Karolinska Institutet, the Stichting af Jochnick Foundation, and the ERC-EYLETS 834860.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Apolipoprotein CIII
- Apoptosis
- Calcium channels
- Inflammation
- Type-1 diabetes
- β-cells
- Apolipoprotein C-III/genetics
- Diabetes Mellitus, Type 1/epidemiology
- Humans
- Insulin-Secreting Cells/metabolism
- Calcium/metabolism
- Diabetes Mellitus, Type 2/genetics
- Inflammation/genetics
- Adult
- Gene Expression Regulation/genetics
Fingerprint
Dive into the research topics of 'Apolipoprotein ciii is an important piece in the type-1 diabetes jigsaw puzzle'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver